Back to Journals » Breast Cancer: Targets and Therapy » Volume 6

Tamoxifen for women at high risk of breast cancer

Authors Nazarali S, Narod S

Received 1 October 2013

Accepted for publication 27 November 2013

Published 17 February 2014 Volume 2014:6 Pages 29—36


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Safia A Nazarali, Steven A Narod

Women's College Research Institute, Women's College Hospital, and The University of Toronto, Toronto, Ontario, Canada

Abstract: Tamoxifen has been used as a treatment for women who have been diagnosed with breast cancer for roughly four decades and has been approved as chemoprevention for over ten years. Although tamoxifen has been proven to be beneficial in preventing breast cancer in high-risk women, its use has not been widely embraced. To some extent, this is due to several of its side effects, including an increased risk of endometrial cancer and pulmonary embolism, but these serious side effects are rare. The risks and benefits of tamoxifen chemoprevention should be considered for each patient.

Keywords: tamoxifen, breast cancer, women, chemoprevention

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]